First clinical postmarketing experiences in the treatment of epilepsies with brivaracetam: a retrospective observational multicentre study

OBJECTIVES: Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of BRV in the clinical setting. DESIGN: Retrospective, observational multicentre study. SETTING: We re...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Menzler, Katja, Mross, Peter Michael, Rosenow, Felix, Schubert-Bast, Susanne, Willems, Laurent Maximilian, Zahnert, Felix, Immisch, Ilka, Fuest, Sven, von Podewils, Felix, Kunz, Rhina, Hirsch, Martin, Mueller, Tamara, Marquetand, Justus, Winter, Yaroslav, Langenbruch, Lisa, Cicanic, Michal, Beyenburg, Stefan, Strzelczyk, Adam, Knake, Susanne
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2019
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858140/
https://ncbi.nlm.nih.gov/pubmed/31690606
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-030746
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars